A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9 Meeting Abstract
| Authors: | Usmani, S. Z.; Mielnik, M.; Byun, J. M.; Alonso, A. A.; Abdallah, A. O. A.; Garg, M.; Quach, H.; Min, C. K.; Janowski, W.; Ocio, E. M.; Weisel, K.; Oriol, A.; Sandhu, I.; Rodríguez-Otero, P.; Ramasamy, K.; Egger, J. L.; Williams, D.; Ma, J.; Kaisermann, M. C.; Hus, M. |
| Abstract Title: | A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9 |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.8018 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 8018 -- Meeting also presented virtually -- Source: Cinahl |
